Navigation Links
GENova gains access to Big Pharma
Date:9/15/2009

NEW YORK, NY, Sept. 15 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch"). GENova expects to generate licensing fees and royalties from the out-licensed manufacturing and marketing rights to leading pharmaceutical companies to exceed more than 5% in a market currently valued at $3billion+ a year over the following 15-20 years which is the duration of the patents.

Bridge BioResearch is an international drug discovery company that focuses on metabolic disorders, and has well-established distribution channels and relationships with leading pharmaceutical companies.

Through a recent collaboration deal, the two companies are working together to leverage their respective Research and Development partners and distribution channels worldwide, with the mutual goal of developing their proprietary drug targets with the utmost cost and time efficiency.

The two companies are both in the business of acquiring early-stage developmental drugs, out-licensing them for development and commercialization, and garnering royalty payments in the process. GENova's focus is oncology, while Bridge BioResearch specializes in Obesity and Type 2 Diabetes drugs. Both companies share a mutual goal of fast-tracking their target drugs through development, clinical studies, licensing to Big Pharma such as Biogen, Elan, Merck's and Genentech.

"This reciprocal arrangement is a huge benefit to both companies," says Aaron Whiteman, CEO for GENova. "I am confident that with our new access to Big Pharma distribution channels we can usher our promising patents through the development process as expeditiously as possible, and ultimately start reaping royalty payments sooner than ever foreseen."


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova issues clarifying press release
10. GENova appoints Dr. Philip Gould to Scientific Advisory Board
11. GENova appoints Dr. Wang Chong to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , ... September 04, 2015 , ... ... CEREC technology is now available at CitiDent. CEREC is a newer method for ... to saving time for patients by eliminating the need for multiple appointments, CEREC ...
(Date:9/4/2015)... Pittsburgh, PA (PRWEB) , ... September 04, 2015 , ... Many consumers are looking for ... Cups could be their solution. , The patent-pending K Med Cups provide a quick and ... they help to relieve a cold, flu or cough. As a result, they enhance comfort ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference ... in Hollywood, Florida October 9-10, 2015 at the Diplomat Resort & Spa has ... are doctors and researchers at the top of their field and will be ...
(Date:9/4/2015)... ... , ... Lalonde Gordon ran a 44.64 seconds scorcher in the third and ... 400 meters final, with an impressive 44.89 seconds at the 2015 North American, Central ... in August 2015. The 44.64 time is a new NACAC Championship record. , ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... details involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what ... with the Vatican and society is. Yisrayl also provides the meaning of his own name ...
Breaking Medicine News(10 mins):Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... , , , SILVER SPRING, ... Wellness Center has selected Artefill, the first and only FDA-approved microsphere-enhanced ... who are looking for a longer lasting dermal filler. Dr. Gonzalez ... to its proven success and effectiveness for the correction of wrinkles. ...
... , , WASHINGTON, Aug. 24 ... Veterans Affairs (VA) is taking steps to assist Veterans seeking compensation ... hidden wounds of war are being addressed vigorously and comprehensively by ... the 21st century," said Secretary Shinseki. , , ...
... , , , , ... the most powerful person in healthcare by readers of Modern ... whose name has become inextricably linked with healthcare reform, topped the ... , , "Think about healthcare reform. Now, try ...
... AUBURN HILLS, Mich., Aug. 24 ... leader in the discovery and development of nanotechnology-enabled, ultraviolet-curable ... collaboration agreement with a major tobacco company for the ... (FSC) cigarettes. FSC cigarettes are designed to meet government ...
... , , , EMERYVILLE, Calif., ... , Inc. (NYSE-Amex: NBY ), a clinical stage ... a wide range of bacterial, viral, and fungal infections, announced today ... the 47th Annual Meeting of the Infectious Diseases Society of America ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
Cached Medicine News:Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Benjamin S. Gonzalez, MD Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Obama Named the Most Powerful Person in Healthcare 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 2Health News:NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5
(Date:9/4/2015)... India , September 4, 2015 ... Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) ... Technology and by Product - Global Forecast to 2020", ... to reach USD 2.5 Billion by 2020, growing at ... 2015 to 2020. Browse 139 Tables ...
(Date:9/4/2015)... 4, 2015  Allergan plc (NYSE: AGN ) a ... , CEO and President of Allergan, will provide an overview ... Global Healthcare Conference 2015 in New York, NY ... The presentation will take place on Thursday, September ... Hyatt New York, 109 East 42nd Street, New ...
(Date:9/4/2015)... Research and Markets ... the "Veterinary Pharmaceutical Submissions in the EU ... to their offering. This practical two-day ... constituent parts of the application for marketing authorisation ... marketing authorisation is sought in the European Union, ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 2Allergan to Present at Morgan Stanley Global Healthcare Conference 2015 3Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2
... Expanding its offering of passive safety devices to protect ... Braun Medical Inc. (B. Braun) recently announced that the ... of the company,s Introcan Safety ® 3 Closed ... Safety ® IV Catheter. B. Braun made the ...
... is well known that ophthalmologists around the world often ... (AMD) over the approved treatment Lucentis (ranibizumabintravitreal) due to ... efficacy. AMD Alliance International (AMDAI) is ... of a concerning surge in eye infections over the ...
Cached Medicine Technology:Safety to the Power of Three: B. Braun Medical Inc. Announces Introcan Safety® 3 Closed IV Catheter 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 2AMD Alliance, Representing AMD Patient Organizations Globally, Encourages Health Care Providers to Stop Using Avastin for Off-Label Ocular Use 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: